中文摘要：

采用Tabashnik的域性状指标分析了新疆MEAM1（Middle—East—Asia—Minor1）烟粉虱隐种对吡虫啉的抗性现实遗传力（h。）和不同致死率下的抗性发展速率，同时测定了抗性种群对不同类型杀虫剂的交互抗性。结果表明，在30％～50％较低的选择压力下，新疆MEAM1烟粉虱隐种连续汰选8代后，对吡虫啉的抗性上升28．01倍，抗性现实遗传力h。为0．4297。假设田间种群现实遗传力为实验室筛选估算值的1／2，即h^2=0．2149，对新疆MEAM1烟粉虱隐种对吡虫啉的抗性发展速率估算结果表明：在药剂选择压力为50％-60％下，若使其对吡虫啉的抗性增长10倍，则需要生长10—8代；而在药剂选择压力为70％～90％下，若使其抗性增长10倍，则仅需要生长6～4代。表明新疆MEAM1烟粉虱隐种对吡虫啉产生抗性的风险很大。交互抗性测定结果显示：抗性种群对同类型的杀虫剂吡虫清和噻虫嗪分别产生了10，78倍和4．75倍的中等至低水平交互抗性；对多杀菌素、毒死蜱、吡丙醚和高效氯氰菊酯的敏感性有所降低；对阿维菌素、氟啶虫胺腈和乙基多杀菌素等杀虫剂则无交互抗性。

英文摘要：

The method of threshold trait analysis described by Tabashnik was used to estimate realized heritability （ h^2 ） of resistance to imidacloprid and the development rate of resistance in Bemisia tabaci Middle-East-Asia-Minor 1 （ MEAM1 ） cryptic species in Xinjiang, and the cross-resistance of resistant population to different insecticides was detected. The results showed that under the ordinary selection pressure 30% -50% ,compared with the original unselected populations,the resistance of MEAM1 to imidacloprid was developed 28.01 times higher after 8 generations by uninterrupted selection, also, the realized heritability（h^2） was 0. 429 7. Given that h^2 of field population was half of those value at 0. 214 9, the risk predicting of resistance of MEAMI to imidacloprid for field population showed that it takes 10- 8 generations to achieve 10-fold resistance under the selection pressure of 50%-60%, and take 6 -4 generations to get the same resistance under the selection pressure of 70%-90%. The results indicated that a high level of risks in the development of resistance to imidacloprid in MEAM1 cryptic species both in field and laboratory conditions. From this detection of cross-resistance, we found that, a medium to low level of cross-resistance to acetamiprid and thiamethoxam which are the same type of insecticides as imidacloprid was obtained at RR = 10. 78-fold and 4.75-fold, respectively, and 2 - 3 folds decrease of susceptibility to spinosad, chlorpyrifos, pyriproxyfen and beta-cypermethrin. And also, very low level or null cross-resistance was observed in the treatment of abamectin, spinetoram and sulfoxaflor.